ST8SIA1

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1

Score: 0.453 Price: $0.45 Low Druggability Status: active Wiki: ST8SIA1

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

DEBATES

3D Protein Structure

🔮 ST8SIA1 — AlphaFold Q92185 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.30

Clinical Stage

Phase II

Target Class

Enzyme

Safety

0.60

Druggability Analysis

Drug Development0.45

Structural Tractability0.30

Target Class0.85

Safety Profile0.60

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (4 compounds)

1 Approved · 2 Preclinical

Druggability Rationale: This enzyme presents druggability challenges — possibly due to a large, flat active site, protein-protein interaction-dependent activity, or lack of chemical starting points. AlphaFold predicted structure available for computational screening. 1 approved drug(s) validate this target pharmacologically.

Mechanism: ST8SIA1 inhibitors would block the synthesis of polysialic acid chains on NCAM, reducing neural cell plasticity and potentially modulating neuroinflammatory responses. This mechanism could be therapeutically relevant for neurodevelopmental disorders or neuroinflammatory conditions where excessive polysialylation contributes to pathology.

Drug Pipeline (4 compounds)

1 Approved · 2 Preclinical

Known Drugs:

Zanamivir (Relenza) (approved) — Influenza; also modulates sialic acid pathways relevant to neuroinflammation

ST8SIA1 inhibitor compound 12a (preclinical) — Neuroinflammation and polysialic acid-related neuropathies

Polysialic acid-targeting monoclonal antibodies (research) — Cancer immunotherapy and neural regeneration models

2,3-dehydro-2-deoxyneuraminic acid derivatives (preclinical) — Sialyltransferase inhibition; neuroprotection studies

Structural Data:

PDB —AlphaFold ✓Cryo-EM —

UniProt: Q92185

🔮 Predicted Protein Structure (AlphaFold)

🔮 ST8SIA1 — AlphaFold Q92185 Click to expand interactive 3D viewer

AI-predicted structure from AlphaFold EBI | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity within the enzyme family is important to avoid mechanism-based toxicity. Isoform-selective inhibitors generally have superior therapeutic windows.

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for Q92185

View AlphaFold Structure

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

Completed

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (0)

No linked hypotheses

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

Debate History (1)

Should ST8SIA1 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1) be2026-04-22

ST8SIA1

3D Protein Structure

Druggability & Clinical Context

🔮 Predicted Protein Structure (AlphaFold)

Selectivity & Safety Considerations

3D Protein Structure (AlphaFold)

Clinical Trials (8)

Linked Hypotheses (0)

Linked Experiments (0)

Scoring Dimensions

Knowledge Graph (20)

associated with (1)

co discussed (3)

downregulates (1)

encodes (1)

expressed in (2)

implicated in (1)

inhibits (1)

interacts with (5)

participates in (1)

product of (1)

protects against (1)

regulates (1)

targets (1)

Debate History (1)